ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,860,977 | $86,996,426 | 0.76% | |
| 2. | Rubric Capital Management David Rosen | 8,540,861 | $68,412,297 | +7% | 0.63% |
| 3. | OrbiMed Advisors Samuel Isaly | 8,288,510 | $66,390,965 | 1.23% | |
| 4. | Deerfield Management James E. Flynn | 7,503,812 | $60,105,534 | 0.63% | |
| 5. | Tyro Capital Management Dan Mcmurtrie | 4,459,337 | $35,719,289 | +51% | 8.01% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.79 | 505,954 | $4,953,289.66 | 9,958,073 | 2024-03-27 | Filing | |
| $9.55 | 457,745 | $4,371,464.75 | 9,452,119 | 2024-03-26 | Filing | |
| $9.06 | 437,600 | $3,964,656.00 | 8,994,374 | 2024-03-25 | Filing | |
| $3.78 | 46,258 | $174,994.01 | 89,227 | 2023-09-29 | Filing | |
| $3.62 | 40,000 | $144,960.00 | 42,969 | 2023-09-28 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 25,000 | $250,000.00 | 12,176 | 2026-06-12 | Filing | |
| $10.00 | 3,355 | $33,550.00 | 90,910 | 2026-06-12 | Filing | |
| $8.71 | 21,828 | $190,049.85 | 10,789 | 2025-11-13 | Filing | |
| $8.86 | 136,380 | $1,208,790.49 | 0 | 2025-11-12 | Filing | |
| $8.91 | 30,000 | $267,357.00 | 136,380 | 2025-11-12 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,311,319 | $42,543,666 | 0% | |
| 2. | 4,170,629 | $33,406,738 | 0.05% | |
| 3. | 3,730,623 | $29,882,290 | 0% | |
| 4. | 2,754,931 | $22,066,997 | 0% | |
| 5. | 2,553,528 | $20,453,759 | 0% |